CA
NZ
UK
AU
IND
US
4D Molecular Therapeutics (NASDAQ: FDMT) revealed that CEO David Kirn executed a sale of 12,415 shares at a weighted average price of $10.05, generating proceeds of roughly $125,000.
NRx Pharmaceuticals (NASDAQ: NRXP) reported that the FDA completed its initial ANDA evaluation of preservative-free ketamine, identifying no significant drug-component flaws.
AVITA Medical (NASDAQ: RCEL) reported second-quarter 2026 financial results and raised its full-year revenue guidance, with executives targeting cash flow breakeven by the fourth quarter behind accelerating commercial momentum and structural efficiency gains.
Insmed Incorporated (NASDAQ: INSM) shares closed up 34% at $132.55 after the company disclosed second-quarter revenue that surpassed analyst projections, propelled by the sustained commercial expansion of ARIKAYCE and Brinsupri.
Ensysce Biosciences, Inc. (NASDAQ: ENSC) shares closed up 45% at $0.52 after the company finalized the acquisition of Cy Biopharma, Inc., integrating the neuroplastogenic candidate CY200 into its development pipeline.
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) shares closed up 43% at $6.21 after the company announced record second-quarter revenue of $99.3 million, representing a 66% year-over-year surge primarily fueled by $91 million in domestic Amtagvi sales.
Akebia Therapeutics, Inc. (NASDAQ: AKBA) shares closed down 26% at $0.95 after the company disclosed second-quarter revenue of $49.1 million, a 21% year-over-year decrease, as a 60% surge in Vafseo sales was overshadowed by a 46% slump in Auryxia revenue due to generic entrants.
Sight Sciences, Inc. (NASDAQ: SGHT) shares closed up 28% at $7.09 after the company reported second-quarter revenue of $23.4 million, representing a robust 19.4% year-over-year increase and exceeding analyst projections.
Context Therapeutics Inc. (NASDAQ: CNTX) shares closed down 27% at $0.50 after the company disclosed a second-quarter net loss of $14.6 million, compared to $8.8 million in the prior year, driven by intensified R&D investment to progress its bispecific antibody portfolio.
BillionToOne, Inc. (NASDAQ: BLLN) shares closed down 39% at $91.65 despite the company disclosing second-quarter revenue of $109.45 million, representing a robust 64% year-over-year increase fueled by a 35% rise in test volume and a 21% improvement in average selling price to $551.
Please wait processing your request...